top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • Jul 16
  • 1 min read

Updated: Jul 21


15/07/2026



  • InnoCare reported Phase 3 results for soficitinib in atopic dermatitis



FDA granted priority review to Roche’s Gazyva for adults with primary membranous nephropathy (Ref)


Roche announced that the US FDA had granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment of primary membranous nephropathy (pMN).


  • The priority review was based on the positive phase 3, MAJESTY results, which showed superiority of obinutuzumab over tacrolimus in adults with pMN.


  • The FDA had already granted Breakthrough Therapy Designation to obinutuzumab in pMN and was expected to make a decision on approval by November 2026.











InnoCare reported Phase 3 results for soficitinib in atopic dermatitis (Ref1; Ref2)


InnoCare Pharma announced that its Phase 3 study for soficitinib ( ICP-332; TYK2 inhibitor), for the treatment of moderate to severe atopic dermatitis had met its primary endpoint.


  • Soficitinib met the primary endpoint with statistically significant, clinically meaningful improvements and achieved multiple secondary endpoints.


  • The drug demonstrated a favorable safety profile, consistent with previous studies, with no new safety signals.


bottom of page